Vaccine Structure Key to Boosting Cancer Immunity, Study Finds

Over the last decade, scientists at Northwestern University have identified a key insight about how vaccines work: the ingredients matter, but the way those ingredients are physically arranged can dramatically influence performance. This principle, now forming the foundation of an emerging field known as “structural nanomedicine,” is showing promise in the development of more effective cancer therapies, particularly for tumors driven by the human papillomavirus (HPV).

Researchers have long understood the importance of what goes *into* a vaccine – the antigens that trigger an immune response and the adjuvants that boost that response. However, this new work demonstrates that *how* those components are organized at the nanoscale is equally critical. Simply adjusting the orientation and position of a single cancer-targeting peptide can significantly strengthen the immune system’s ability to attack tumors, according to a study published on February 11, 2026, in Science Advances.

Testing a Spherical Nucleic Acid Vaccine

To explore this concept, the team designed a vaccine based on spherical nucleic acids (SNAs) – globular DNA structures that naturally enter and stimulate immune cells. They then systematically reorganized the components within the SNA in several different configurations. These versions were tested in humanized animal models of HPV-positive cancer and in tumor samples taken from patients with head and neck cancer.

One particular configuration consistently outperformed the others, reducing tumor growth, prolonging survival in animals, and generating greater numbers of highly active cancer-killing T cells. The findings highlight that even a subtle change in how vaccine components are arranged can determine whether a nanovaccine produces a limited immune response or a powerful, tumor-destroying effect.

“There are thousands of variables in the large, complex medicines that define vaccines,” said Chad A. Mirkin, the George B. Rathmann Professor of Chemistry, Chemical and Biological Engineering, Biomedical Engineering, Materials Science and Engineering, and Medicine at Northwestern, who led the study. “The promise of structural nanomedicine is being able to identify from the myriad possibilities the configurations that lead to the greatest efficacy and least toxicity. In other words, we can build better medicines from the bottom up.” Mirkin also directs the International Institute of Nanotechnology and is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Moving Beyond the Traditional “Blender Approach”

Conventional vaccine development often relies on a “blender approach,” combining key ingredients without precise structural control. In cancer immunotherapy, this typically involves pairing tumor-derived molecules called antigens with immune-stimulating compounds known as adjuvants, mixing them together, and administering the resulting formulation.

Mirkin describes this method as lacking defined organization. “If you look at how drugs have evolved over the last few decades, we have gone from well-defined small molecules to more complex but less structured medicines,” he said. “The COVID-19 vaccines are a beautiful example — no two particles are the same. While very impressive and extremely useful, we can do better, and, to create the most effective cancer vaccines, we will have to.”

Research from Mirkin’s laboratory demonstrates that arranging antigens and adjuvants into carefully designed nanoscale structures can significantly improve outcomes. When configured properly, the same ingredients can deliver stronger effects with lower toxicity compared to unstructured mixtures.

Strengthening the Immune Response to HPV Cancers

The recent study focused on cancers caused by HPV, which is responsible for most cervical cancers and a growing percentage of head and neck cancers. While preventative HPV vaccines exist to stop infection, there is a need for therapies to treat cancers that have already developed.

To address this, the researchers created therapeutic vaccines designed to activate CD8 “killer” T cells, the immune system’s most potent cancer-fighting cells. Each nanoparticle included a lipid core, immune-activating DNA, and a short fragment of an HPV protein already present in tumor cells. The only variable tested was the position and orientation of the HPV-derived peptide, or antigen.

The researchers tested three designs. In one, the peptide was hidden inside the nanoparticle. In the other two, it was displayed on the surface, attached at either the N terminus or the C terminus – a subtle difference that can influence how immune cells recognize and process it. The version presenting the antigen on the surface attached via its N-terminus produced the strongest immune reaction, triggering up to eight times more interferon-gamma, an important anti-tumor signal released by killer T cells. These T cells were also substantially more effective at destroying HPV-positive cancer cells. In humanized mouse models, tumor growth slowed markedly, and in tumor samples from HPV-positive cancer patients, cancer cell killing increased by twofold to threefold.

“This effect did not come from adding new ingredients or increasing the dose,” explained Dr. Jochen Lorch, a professor of medicine at Northwestern’s Feinberg School of Medicine and the medical oncology director of the Head and Neck Cancer Program at Northwestern Medicine. “It came from presenting the same components in a smarter way. The immune system is sensitive to the geometry of molecules. By optimizing how we attach the antigen to the SNA, the immune cells processed it more efficiently.”

Looking Ahead: AI and Vaccine Redesign

Mirkin plans to revisit earlier vaccine candidates that showed promise but didn’t generate strong enough immune responses in patients. By demonstrating that nanoscale structure directly influences immune potency, this research offers a framework for improving therapeutic cancer vaccines using existing components, potentially speeding up development and reducing costs.

He also anticipates that artificial intelligence will play an increasingly important role in vaccine design. Machine learning systems could rapidly analyze vast numbers of structural combinations to identify the most effective arrangements.

“This approach is poised to change the way we formulate vaccines,” Mirkin said. “We may have passed up perfectly acceptable vaccine components simply because they were in the wrong configurations. We can go back to those and restructure and transform them into potent medicines. The whole concept of structural nanomedicines is a major train roaring down the tracks. We have shown that structure matters – consistently and without exception.”

The study, “E711-19 placement and orientation dictate CD8+ T cell response in structurally defined spherical nucleic acid vaccines,” was supported by the National Cancer Institute (award numbers R01CA257926 and R01CA275430), the Lefkofsky Family Foundation and Robert H. Lurie Comprehensive Cancer Center of Northwestern University.